ASSOCIATION OF C-REACTIVE PROTEIN WITH HYPERLIPIDEMIA IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME IN KHYBER PAKHTUNKHWA

Authors

  • Sobia Ali Department of Biochemistry, Khyber Medical College, Peshawar
  • Hajira Ishaq Department of Biochemistry, Khyber Medical College, Peshawar
  • Naheed Khattak Department of Biochemistry, Khyber Medical College, Peshawar
  • Sadaf Durrani Department of Biochemistry, Khyber Medical College, Peshawar
  • Ubaid ur Rehman Department of Biochemistry, Khyber Medical College, Peshawar
  • Romana Irshad Department of Pathology,Ayub Medical College, Abbottabad
  • Mudassir Ahmad Khan Department of Biochemistry, Khyber Medical College, Peshawar

DOI:

https://doi.org/10.55519/JAMC-03-10836

Abstract

Background: It has been unknown whether there exist any relations of C-Reactive Protein (CRP) level with hyperlipidaemia in polycystic ovarian syndromes patients. To determine Association of CRP with Hyperlipidaemia in patients with polycystic ovarian syndrome. Method: This was a cross sectional descriptive study conducted among 50 each polycystic ovarian syndrome and normal women. After taking a written consent from participants predesigned questionnaire was filled including information regarding demography and medical history. A 3 to 5 ml blood was taken from patients and controls and transferred to laboratory for determination of CRP level and lipid profile. The test results were collected, compiled, entered and analyzed using SPSS Version 20 for determination of any kind of association of CRP with Hyperlipidaemia in patients with polycystic ovarian syndrome. Results: The mean age of study participants was 29.72±4.00 for cases and 29.04±3.99 for control. The cases and control were with the same age range, however there was a significant difference p=0.00 in BMI of the cases and control. There was no significant association observed between CRP and lipid profile parameters among polycystic ovarian syndrome patients. Conclusion: There exist no association between increasing CRP level and hyperlipidaemia in polycystic ovarian syndrome patients however CRP and lipid profile parameters showed high values among these patients.

References

Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers 2016;2:16057.

Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97:28–38.e25.

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reprod 2004;19(1):41–7.

Goodarzi MO, Quiñones MJ, Azziz R, Rotter JI, Hsueh WA, Yang H. et al. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril 2005;84(3):766–9.

Zhu T, Cui J, Goodarzi MO. Polycystic ovary syndrome and risk of type 2 diabetes, coronary heart disease, and stroke. Diabetes 2021;70(2):627–37.

Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr Diab Rep 2006;6(1):77–83.

Orio F, Muscogiuri G, Nese C, Palomba S, Savastano S, Tafuri D, et al. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2016;207:214–9.

Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349(9050):462–6.

Macut D, Bačević M, Božić-Antić I, Bjekić-Macut J, Čivčić M, Erceg S, et al. Predictors of subclinical cardiovascular disease in women with polycystic ovary syndrome: interrelationship of dyslipidemia and arterial blood pressure. Int J Endocrinol 2015;2015:812610.

Ridker PM, Glynn RJ and Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97(20):2007–11.

Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342(12):836–43.

Bahceci M, Tuzcu A, Canoruc N, Tuzun Y, Kidir V, Aslan C. Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Horm Res Paediatr 2004;62:283–7.

Moradi S, Mollabashi M, Jafarian Kerman SR. Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome. Gynecol Endocrinol 2011;27:480–5.

Nasiek M, Kos-Kudla B, Ostrowska Z, Marek B, Kudla M, Siemińska L, et al. Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome. Pathophysiology 2007;14(1):23–8.

Kalra A, Nair S, Rai L. Association of obesity and insulin resistance with dyslipidemia in Indian women with polycystic ovarian syndrome. Indian J Med Sci 2006;60(11):447–53.

Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci 2013;56(3):137–42.

Downloads

Published

2022-09-29

Most read articles by the same author(s)